Parallel Advisors
SGYP

Parallel Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Parallel Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-184
Closed -$1K – 2278
2017
Q1 		$1K Buy
+184
New +$1.07K ﹤0.01% 1965

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Parallel Advisors's SGYP Position: Q2 2017 in Review

Parallel Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2017, closing a stake of 184 shares — an estimated $1K sold.

Parallel Advisors first reported a position in SGYP in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 146 funds tracked by Wall St. Rank hold SGYP as of Q2 2017.

  • Parallel Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2017 after selling out during the quarter.
  • Parallel Advisors sold 184 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2017, an estimated $1K.
  • Parallel Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2017 and held it in 1 quarter.
  • Parallel Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $1K in Q1 2017.
  • 146 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2017.

Based on Parallel Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.